SLGL
Sol-Gel Technologies Ltd
NASDAQ · Pharmaceuticals
$65.78
+1.08 (+1.67%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 88.52M | 80.43M | 74.82M |
| Net Income | 26.33M | 27.17M | 21.09M |
| EPS | — | — | — |
| Profit Margin | 29.7% | 33.8% | 28.2% |
| Rev Growth | +7.8% | -4.6% | -5.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 48.67M | 45.73M | 50.34M |
| Total Equity | 120.24M | 128.24M | 118.27M |
| D/E Ratio | 0.40 | 0.36 | 0.43 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 47.92M | 38.14M | 36.98M |
| Free Cash Flow | 19.52M | 15.33M | 13.15M |